Search
Research
Community immunity: Developing a sensitive and specific SARS-CoV-2 antibody testPeter Richmond PC MBBS MRCP(UK) FRACP Head, Vaccine Trials Group Head, Vaccine Trials Group Professor Peter Richmond is Head of the Vaccine Trials
Research
Does mum know best? Should we be vaccinating mothers to protect their babies from ear and lung disease?Elke Lea-Ann Ruth Peter Seppanen Kirkham Thornton Richmond ES LK RT PC BSc PhD PhD PhD MBBS MRCP(UK) FRACP Program Manager, Bacterial Respiratory
Research
Impact of Repeat Pertussis Vaccination on Infant and Maternal Antibody QualityRuth Peter Thornton Richmond RT PC PhD MBBS MRCP(UK) FRACP Co-head, Bacterial Respiratory Infectious Disease Group (BRIDG) Head, Vaccine Trials Group
Research
An infant mouse model of influenza-driven nontypeable Haemophilus influenzae colonization and acute otitis media suitable for preclinical testing of novel therapiesNontypeable Haemophilus influenzae (NTHi) is a major otitis media (OM) pathogen, with colonization a prerequisite for disease development. Most acute OM is in children <5 years old, with recurrent and chronic OM impacting hearing and learning. Therapies to prevent NTHi colonization and/or disease are needed, especially for young children. Respiratory viruses are implicated in driving the development of bacterial OM in children.